Limited hospital access for the first six months of the 2022 financial year has not stopped billion-dollar wound and burn treatment biotech PolyNovo from achieving substantial revenue growth, surging 42.8 per cent to $41.9 million.

But this didn’t stop investors pushing down its shares by 18.8 per cent to $1.64 on Friday, disappointed by another year of earnings losses. Analysts had been expecting PolyNovo to achieve positive earnings before interest, tax, depreciation and amortisation of $1.6 million, according to Bloomberg, but PolyNovo banked just $800,000.